Contraceptive choices for women with endocrine complications

D. Lynn Loriaux, Robert A. Wild

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Previous confusion regarding the interference by oral contraceptives in measurements of endocrine function have been largely eliminated by the advent of improved, more sensitive assays. There are few if any contraindications to oral contraceptive use in patients with thyroid disease. Patients with prolactinoma can be treated with bromocriptine to restore fertility and prevent mineral loss. However, as a less expensive alternative, oral contraceptives can be prescribed to correct mineral loss, because there is no convincing evidence of an adverse effect on prolactinomas by the steroidal content of the pill. Oral contraceptives comprise a near ideal treatment modality for women with polycystic ovary disease because, among other effects, oral contraceptives reduce synthesis of androgen by inhibiting pituitary gonadotropin secretion. (AM J OBSTET GVNECOL 1993;168:2021-6.)

Original languageEnglish (US)
Pages (from-to)2021-2026
Number of pages6
JournalAmerican journal of obstetrics and gynecology
Issue number6
StatePublished - 1993


  • Contraception
  • hirsutism
  • polycystic ovary disease
  • sex hormones
  • thyroid disease

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Contraceptive choices for women with endocrine complications'. Together they form a unique fingerprint.

Cite this